This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McGregor, D. O. Articles by Nicholls, M. G. Search for Related Content PubMed PubMed Citation Articles by McGregor, D. O. Articles by Nicholls, M. G. Related Collections Other hypertension

(Hypertension. 2001;37:1279.)
© 2001 American Heart Association, Inc.

Scientific Contributions

Hypotensive and Natriuretic Actions of Adrenomedullin in Subjects With Chronic Renal Impairment

David O. McGregor¹; Richard W. Troughton¹; Christopher Frampton; Kelvin L. Lynn; Timothy Yandle; A. Mark Richards; M. Gary Nicholls

From the Cardioendocrine Research Group (R.W.T., C.F., T.Y., A.M.R., G.N.) and the Department of Nephrology (D.O.M., K.L.L.), Christchurch Hospital, Christchurch, New Zealand.

Correspondence to Dr D. McGregor, Department of Nephrology, Christchurch Hospital, Private Bag 4710, Christchurch, New Zealand. E-mail davidm2{at}chhlth.govt.nz

Abstract—Plasma levels of adrenomedullin are increased in chronic renal failure. The significance of this finding is uncertain, because the biological effects of adrenomedullin in renal impairment are unknown. Therefore, we studied the effects of adrenomedullin infusion in subjects with chronic renal impairment. Eight males with IgA nephropathy and plasma creatinine of 0.19±0.03 mmol/L (mean±SEM) were studied in a vehicle-controlled crossover design. Each subject was studied twice; subjects were administered either adrenomedullin at a low dose and then a high dose (2.9 and 5.8 pmol/kg per minute, respectively, for 2 hours each) or a 4-hour vehicle control (Hemaccel), in random order, on day 4 of controlled metabolic diets. Adrenomedullin infusion achieved plasma adrenomedullin concentrations in the pathophysiological range after the low (31.2±5.1 pmol/L) and high (47.4±4.3 pmol/L) dose, and plasma cAMP was increased. Compared with vehicle control, high-dose adrenomedullin increased peak heart rate (+21.7±3.3 bpm, P<0.01) and cardiac output (+2.9±0.2 L/min, P<0.01) and lowered both systolic and diastolic blood pressures by >10 mm Hg (P<0.05). Plasma renin activity, angiotensin II, and norepinephrine increased by up to 50% above baseline levels (P<0.05 for all), whereas aldosterone and epinephrine were unchanged. Urinary volume and sodium excretion increased significantly (P<0.05) with low-dose adrenomedullin, whereas creatinine clearance was stable, and proteinuria tended to decrease. In subjects with chronic renal impairment due to IgA nephropathy, adrenomedullin infusion lowered blood pressure, stimulated sympathetic activity and renin release, and caused diuresis and natriuresis. Adrenomedullin may have a role in modulating blood pressure and kidney function in renal disease.

Key Words: adrenomedullin • renal disease • immunoglobulins • proteinuria • renin • angiotensin II • sympathetic nervous system

This article has been cited by other articles:

				M. Kjolby and P. Bie Chronic activation of plasma renin is log-linearly related to dietary sodium and eliminates natriuresis in response to a pulse change in total body sodium Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2008; 294(1): R17 - R25. [Abstract] [Full Text] [PDF]

				R. Schnabel, E. Lubos, H. J. Rupprecht, C. Espinola-Klein, C. Bickel, K. J. Lackner, F. Cambien, L. Tiret, T. Munzel, and S. Blankenberg B-Type Natriuretic Peptide and the Risk of Cardiovascular Events and Death in Patients With Stable Angina: Results From the AtheroGene Study J. Am. Coll. Cardiol., February 7, 2006; 47(3): 552 - 558. [Abstract] [Full Text] [PDF]

				C J Charles, D L Jardine, M G Nicholls, and A M Richards Adrenomedullin increases cardiac sympathetic nerve activity in normal conscious sheep J. Endocrinol., November 1, 2005; 187(2): 275 - 281. [Abstract] [Full Text] [PDF]

				M. M. Taylor, J. R. Baker, and W. K. Samson Brain-derived adrenomedullin controls blood volume through the regulation of arginine vasopressin production and release Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2005; 288(5): R1203 - R1210. [Abstract] [Full Text] [PDF]

				T. Fujii, N. Nagaya, T. Iwase, S. Murakami, Y. Miyahara, K. Nishigami, H. Ishibashi-Ueda, M. Shirai, T. Itoh, K. Ishino, et al. Adrenomedullin enhances therapeutic potency of bone marrow transplantation for myocardial infarction in rats Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1444 - H1450. [Abstract] [Full Text] [PDF]

				M. Pfister, N. E. Martin, L. P. Haskell, and J. S. Barrett Optimizing Dose Selection with Modeling and Simulation: Application to the Vasopeptidase Inhibitor M100240 J. Clin. Pharmacol., June 1, 2004; 44(6): 621 - 631. [Abstract] [Full Text] [PDF]

				W. Nowak, N. Parameswaran, C. S. Hall, N. Aiyar, H. V. Sparks, and W. S. Spielman Novel regulation of adrenomedullin receptor by PDGF: role of receptor activity modifying protein-3 Am J Physiol Cell Physiol, June 1, 2002; 282(6): C1322 - C1331. [Abstract] [Full Text] [PDF]